HOOKIPA Pharma Inc. announced that Klaus Orlinger, Ph.D. has been promoted to Chief Scientific Officer. Since joining HOOKIPA in February 2012, Klaus has played a leading role in driving HOOKIPA's arenaviral platform to the clinic and demonstrating the potent antigen-specific T cell response these novel immunotherapies induce. Klaus Orlinger, Ph.D. joined HOOKIPA in 2012 as the Head of Virology and was responsible for the generation and characterization of prophylactic and therapeutic immunotherapy candidates, as well as coordination with international research collaboration partners.

He has held roles of increasing responsibility since that time, most recently serving as Executive Vice President, Research. Klaus began his career as a scientist in the molecular vaccines department at Baxter AG. He is a published author and holds several patents for arenaviral vectors and candidate immunotherapies.

Klaus earned his undergraduate degree, Masters' degree and Ph.D. in microbiology and genetics from the University Vienna.